Kim, Yoon Kim, Unyong Kim, In Sook Lee, Sung-Hack Lee, Jaeick Kim, Dong-Hyun Yoo, Hye Hyun 2024-01-20T09:32:26Z 2024-01-20T09:32:26Z 2021-09-04 2014-07 0049-8254 https://pubs.kist.re.kr/handle/201004/126663 1. The absorption, distribution, metabolism and excretion of a novel dipeptidyl peptidase IV inhibitor, gemigliptin, were examined following single oral administration of C-14-labeled gemigliptin to rats. 2. The C-14-labeled gemigliptin was rapidly absorbed after oral administration, and its bioavailability was 95.2% (by total radioactivity). Distribution to specific tissues other than the digestive organs was not observed. Within 7 days after oral administration, 43.6% of the administered dose was excreted via urine and 41.2% was excreted via feces. Biliary excretion of the radioactivity was about 17.7% for the first 24 h. After oral administration of gemigliptin to rats, the in vivo metabolism of gemigliptin was investigated with bile, urine, feces, plasma and liver samples. 3. The major metabolic pathway was hydroxylation, and the major circulating metabolites were a dehydrated metabolite (LC15-0516) and hydroxylated metabolites (LC15-0635 and LC15-0636). English INFORMA HEALTHCARE DOUBLE-BLIND PHARMACOKINETICS LC15-0444 PHARMACODYNAMICS MULTICENTER VOLUNTEERS EFFICACY SAFETY TRIAL Absorption, distribution, metabolism and excretion of gemigliptin, a novel dipeptidyl peptidase IV inhibitor, in rats Article 10.3109/00498254.2013.873156 1 XENOBIOTICA, v.44, no.7, pp.627 - 634 XENOBIOTICA 44 7 627 634 scie scopus 000337020100005 2-s2.0-84901975181 Pharmacology & Pharmacy Toxicology Pharmacology & Pharmacy Toxicology Article DOUBLE-BLIND PHARMACOKINETICS LC15-0444 PHARMACODYNAMICS MULTICENTER VOLUNTEERS EFFICACY SAFETY TRIAL Absorption distribution excretion gemigliptin metabolism